SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2021 / Cilt: 3 - Sayı: Supplement 1

A peripartum cardiomyopathy case treated with bromocriptine

Şeyda GÜNAY
Osman Akın SERDAR
Dilek YEŞİLBURSA
Sümeyye GÜLLÜLÜ
Naile Bolca TOPAL
Pages
117–119
Publication Date
2021-03-07
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Patients with peripartum cardiomyopathy may benefit from bromocriptine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Peripartum cardiomyopathy is a rare disease that is difficult to diagnose and treat.
📊
Key Findings & Data:Case Report: A 32-year-old woman presented with symptoms of heart failure 4 days after first delivery.
💡
Conclusion & Impact:Conclusion: Patients with peripartum cardiomyopathy may benefit from bromocriptine.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:peripartum · heart · failure

Abstract

Introduction: Peripartum cardiomyopathy is a rare disease that is difficult to diagnose and treat. Clinical findings are similar with heart failure. New treatments are needed in addition to the treatment of heart failure. Case Report: A 32-year-old woman presented with symptoms of heart failure 4 days after first delivery. Chest X-ray showed cardiomegaly. Serum BNP level was high. Transthoracic echocardiography (TTE) indicated dilated left atrium and left ventricle, severe mitral regurgitation and ventricular dysfunction. The global longitudinal strain was – 9.1%. Cardiac magnetic resonance imaging (MRI) revealed mid-myocardial staining detected in late phase images. Concomitant bromocriptine (2,5 mg po twice a day for 15 days and then 2,5 mg po once a day for 15 days) was used with standard heart failure therapy. At 6 months, TTE and cardiac MRI revealed normal biventricular function and size. Global longitudinal strain was –14%. Conclusion: Patients with peripartum cardiomyopathy may benefit from bromocriptine.

🔖

Cite This Article

GÜNAY, Ş., SERDAR, O. A., YEŞİLBURSA, D., GÜLLÜLÜ, S., TOPAL, N. B. (2021). A peripartum cardiomyopathy case treated with bromocriptine. Turkish Journal of Internal Medicine, Cilt: 3 - Sayı: Supplement 1, 117–119. https://ajindex.com/articles/809098

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Mubarik A, Chippa V, Iqbal AM. Postpartum Cardiomyopathy. [Updated 2020 Aug 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from:
  2. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000;283:1183-8
  3. Dinic V, Markovic D, Savic N, Kutlesic M, Jankovic RJ. Peripartum Cardiomyopathy in Intensive Care Unit. Front Med (Lausanne) 2016;3:18
  4. Ansari AA, Fett JD, Carraway RD, Mayne AE, Onlamoon M, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002;23:289-312
  5. Felker GM, Jaeger CJ, Klodas E, Thiemann DR, Hare JM, Hruban RH, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000;140:785-91
  6. Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL. Peripartum myocarditis and cardiomyopathy.Circulation 1990;81:922-8
  7. Neligan JP, Laffey JG. Clinical review: Special populations- critical illness and pregnancy. Crit Care 2011;15:227
  8. Biteker M, Duran NE, Ozkan M. The role of bromocriptine in peripartum cardiomyopathy. Am J Obstet Gynecol 2009; 201:e13
  9. Elkayam U, Tummala PP, Rao K, Akhter MW, Karaalp IS, Wani OR, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001;344:1567-71.